Macular Degeneration Therapeutics Market is Forecast to Show High Growth Rate, Doubling in Size by 2017

Macular Degeneration - Pipeline Assessment and Market Forecasts to 2017 is an essential source of information and analysis on the global Macular Degeneration market. The report identifies the key trends shaping and driving the global Macular Degeneration market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Macular Degeneration sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The authors valued the global macular degeneration therapeutics market at $1.3 billion in 2009. It is expected to grow to $3.0 billion with a Compound Annual Growth Rate (CAGR) of 10.4% by 2017. This growth is primarily attributed to the increase in the aged population across the world. Macular degeneration is a common disease that affects people above 50 years of age. Incidence is high in patients who are above 70 years. The growth will be supported by increased competition between the traditionally used off label products and the newly approved drugs and is expected to continue in the future. In 2009, Lucentis (ranibizumab), a blockbuster drug from Genentech, was the leading player in the global macular degeneration therapeutics market. Avastin is one of Genentech's blockbuster drugs, approved for various types of cancer. Avastin was widely used as an off-label drug by patients with macular degeneration before the approval of Lucentis.

Competition in the Macular Degeneration Therapeutics Market is Expected to Intensify The leading companies in the global macular degeneration therapeutics market are Genentech, Osi Eyetech Inc. and QLT Ltd. Together, these companies accounted for more than 95% of the global macular degeneration therapeutics market in 2009.

Genentech, with its blockbuster drug Lucentis, was the market leader with a share of more than 90%, followed by Visudyne (verteporfin). However, companies such as Novartis AG, Bayer/Regeneron Pharma, Adeona Pharma, Ophthotech Corp, Alcon Inc, Pfizer Inc, Acucela Inc, Alimera Sciences, Neurotech Pharma and Allergan Inc have the most technologically advanced products in their pipeline portfolios and are expected to attract most of the investors attention. The global macular degeneration therapeutics market has seen some intense competition in recent times, which is expected to further intensify over the coming years.

GlobalData, the industry analysis specialist, has released its new report, Macular Degeneration - Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global Macular Degeneration market. The report identifies the key trends shaping and driving the global Macular Degeneration market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Macular Degeneration sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts.

GlobalData valued the global macular degeneration therapeutics market at $1.3 billion in 2009. It is expected to grow to $3.0 billion with a Compound Annual Growth Rate (CAGR) of 10.4% by 2017. This growth is primarily attributed to the increase in the aged population across the world. Macular degeneration is a common disease that affects people above 50 years of age. Incidence is high in patients who are above 70 years. The growth will be supported by increased competition between the traditionally used off label products and the newly approved drugs and is expected to continue in the future. In 2009, Lucentis (ranibizumab), a blockbuster drug from Genentech, was the leading player in the global macular degeneration therapeutics market. Avastin is one of Genentechs blockbuster drugs, approved for various types of cancer. Avastin was widely used as an off-label drug by patients with macular degeneration before the approval of Lucentis.

Scope The report provides information on the key drivers and challenges of the Macular Degeneration market. Its scope includes: Annualized global Macular Degeneration market revenues data from 2001 to 2009, forecast for eight years to 2017. Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as VEGF inhibitors, angiogenesis inhibitors, C5a receptor antagonists, antioxidants, tyrosine kinase inhibitosr, clotting factor inhibitors, cyclooxygenase inhibitors, RPE inhibitors, antioxidants, PDGF inhibitors, chemokine inhibitors, IL-2 inhibitors, retinol protein binders, a51 integrin antagonist, protein C3 inhibitors and mRNA targeting agents. Analysis of the current and future competition in the global Macular Degeneration market. Key market players covered are Novartis AG, Bayer Pharma, Adeona Pharma, Ophthotech Corp., Alcon Inc, Pfizer Inc, Acucela Inc, Alimera Sciences, Neurotech Pharma, and Allergan Inc. Insightful review of the key industry drivers, restraints and challenges.

Each trend is independently researched to provide a qualitative analysis of its implications. Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Macular Degeneration therapeutics market.

Reasons to buy The report will enhance your decision making capability. It will allow you to: Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the global Macular Degeneration market. Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Macular Degeneration market in future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. What's the next big thing in the global Macular Degeneration market landscape? Identify, understand and capitalize.

Key Topics Covered: 1 Summary 2 Macular Degeneration Therapeutics: Disease Overview 3 Macular Degeneration Therapeutics: Market Characterization 4 Macular Degeneration Therapeutics: Competitive Assessment 5 Macular Degeneration Therapeutics: Pipeline Assessment 6 Global Macular Degeneration Therapeutics: Implications for Future Market Competition 7 Macular Degeneration Therapeutics: Future Players in the Macular Degeneration Disease Market 8 Macular Degeneration Therapeutics: Appendix Companies Mentioned: Alcon Inc. Novartis AG Ophthotech Corporation Pfizer Inc Acucela Inc. Regeneron Pharmaceuticals, Inc.